Skip to main content
Publications
Russell MA, Dharmage S, Fuertes E, Marcon A, Carsin AE , Pascual Erquicia S, Heinrich J, Johannessen A, Abramson MJ, Amaral AFS, Cerveri I, Demoly P, Garcia-Larsen V, Jarvis D, Martinez-Moratalla J, Nowak D, Palacios-Gomez L, Squillacioti G, Raza W, Emtner M, Garcia-Aymerich J. The effect of physical activity on asthma incidence over 10 years: population-based study . ERJ Open Res. 2021 Mar 1;7(1):00970-202. doi: 10.1183/23120541.00970-2020
Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, Gold AL , Manly JJ, Mayeda ER, Filshtein TJ, Power MC, Elahi FM, Brickman AM, Glymour MM. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis . BMJ. 2021 Feb 25;372:n156. doi: 10.1136/bmj.n156
van der Wall SJ, Teutsch C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ , Paquette M, Zint K, Franca LR, Lu S, Lip GYH, Huisman MV, GLORIA-AF Investigators. Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF . TH Open. 2021 Feb 6;5(1):e35-42. doi: 10.1055/s-0040-1722706
Wintzer-Wehekind J, Horlick E, Ibrahim R, Cheema AN, Labinaz M, Nadeem N, Osten M, Cote M, Marsal JR , Rivest D, Marrero A, Houde C, Rodes-Cabau J. Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: one-year results of the CANOA randomized clinical trial . JAMA Cardiol. 2021 Feb 1;6(2):209-13. doi: 10.1001/jamacardio.2020.4297
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Lytras T, Beckmeyer-Borowko A, Kogevinas M, Kromhout H, Carsin AE , Anto JM, Bentouhami H, Weyler J, Heinrich J, Nowak D, Urrutia I, Martinez-Moratalla J, Gullon JA, Pereira Vega A, Raherison Semjen C, Pin I, Demoly P, Leynaert B, Villani S, Gislason T, Svanes O, Holm M, Forsberg B, Norback D, Mehta AJ, Keidel D, Vernez D, Benke G, Jogi D, Toren K, Sigsgaard T, Schlunssen V, Olivieri M, Blanc PD, Watkins J, Bono R, Squillacioti G, Buist AS, Vermeulen R, Jarvis D, Probst-Hensch N, Zock JP. Cumulative occupational exposures and lung-function decline in two large general-population cohorts . Ann Am Thorac Soc. 2021 Feb;18(2):238-46. doi: 10.1513/AnnalsATS.202002-113OC
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H , Ling C , Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057 . Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Garcia Del Blanco B, Otaegui I, Rodriguez-Palomares JF, Bayes-Genis A, Fernandez-Nofrerias E, Vilalta Del Olmo V, Carrillo X, Ibanez B, Worner F, Casanova J, Pueo E, Gonzalez-Juanatey JR, Lopez-Pais J, Bardaji A, Bonet G, Fuertes M, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gomez-Talavera S, Marti G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MA, Miro-Casas E, Marsal JR , Sambola A, Lidon RM, Baneras J, Elizaga J, Padilla F, Barrabes JA, Hausenloy DJ, Ferreira-Gonzalez I, Garcia-Dorado D. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI) . Basic Res Cardiol. 2021 Jan 25;116(1):4. doi: 10.1007/s00395-021-00842-2
Dong OM , Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program . Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173
Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J , Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC) . Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.
McIntyre RS, Patel MD, Masand PS, Harrington A, Gillard P, McElroy SL, Sullivan K, Montano CB, Brown TM , Nelson L , Jain R. The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder . Curr Med Res Opin. 2021 Jan;37(1):135-44. doi: 10.1080/03007995.2020.1860358
Taylor MH, Leboulleux S, Panaseykin S, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D , Sherif B , Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life (HRQoL) analyses from study 211: a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN) . Poster presented at the 46th Congress of European Society for Medical Oncology (ESMO); September 16, 2021. [abstract] Ann Oncol. 2021; 32(suppl_5):S1205-10. doi: 10.1016/annonc/annonc715